Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observation Study (SWOG S2013)
This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer. In the future, this information may help doctors make better decisions about cancer treatments.
Contact
Clinical Trials Office at [email protected] or (203) 358-8879.
Principal Investigator(s)
Salvatore Del Prete, MD
Sponsor(s)
Southwest Oncology Group
Location
Bennett Cancer Center
Stamford, CT 06902
Main: 203-358-8879